WO2003097661A3 - Antiviral phosphorothioate oligonucleotides - Google Patents

Antiviral phosphorothioate oligonucleotides Download PDF

Info

Publication number
WO2003097661A3
WO2003097661A3 PCT/US2003/011593 US0311593W WO03097661A3 WO 2003097661 A3 WO2003097661 A3 WO 2003097661A3 US 0311593 W US0311593 W US 0311593W WO 03097661 A3 WO03097661 A3 WO 03097661A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorothioate oligonucleotides
antiviral
oligonucleotides
hiv
phosphorothioate
Prior art date
Application number
PCT/US2003/011593
Other languages
French (fr)
Other versions
WO2003097661A2 (en
Inventor
Zhidong Chen
Duane Ruffner
Richard Koehn
Dinesh Patel
Original Assignee
Salus Therapeutics
Zhidong Chen
Duane Ruffner
Richard Koehn
Dinesh Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salus Therapeutics, Zhidong Chen, Duane Ruffner, Richard Koehn, Dinesh Patel filed Critical Salus Therapeutics
Priority to AU2003223619A priority Critical patent/AU2003223619A1/en
Publication of WO2003097661A2 publication Critical patent/WO2003097661A2/en
Publication of WO2003097661A3 publication Critical patent/WO2003097661A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

The present invention relates to antiviral compositions, agents, and methods of use. In particular, a phosphorothioate oligonucleotide with an optimized chain length is presented. Such phosphorothioate oligonucleotides have a chain length of at least 32 nucleotides and may be further optimized by having about 37 oligonucleotides. The phosphorothioate oligonucleotides of the present invention may be used in methods of inhibiting HIV activity, including the activity of HIV-1 and HIV-2.
PCT/US2003/011593 2002-05-13 2003-04-16 Antiviral phosphorothioate oligonucleotides WO2003097661A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003223619A AU2003223619A1 (en) 2002-05-13 2003-04-16 Antiviral phosphorothioate oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14436002A 2002-05-13 2002-05-13
US10/144,360 2002-05-13

Publications (2)

Publication Number Publication Date
WO2003097661A2 WO2003097661A2 (en) 2003-11-27
WO2003097661A3 true WO2003097661A3 (en) 2004-05-13

Family

ID=29548252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011593 WO2003097661A2 (en) 2002-05-13 2003-04-16 Antiviral phosphorothioate oligonucleotides

Country Status (2)

Country Link
AU (1) AU2003223619A1 (en)
WO (1) WO2003097661A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498777C (en) 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOULME ET AL.: "Modified (PNA, 2'-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription", NUCLEIC ACID RESEARCH, vol. 26, no. 23, 1998, pages 5492 - 5500, XP002177597 *

Also Published As

Publication number Publication date
WO2003097661A2 (en) 2003-11-27
AU2003223619A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
RU2010119292A (en) INTERFERABLE RNA DUPLEX HAVING "DULL" ENDS AND 3'-MODIFICATIONS
MXPA05002791A (en) Non-sequence complementary antiviral oligonucleotides.
DK0691980T3 (en) 7-deazapurine-modifying oligonucleotides
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
EP0637316A4 (en) Antisense oligonucleotide inhibition of papillomavirus.
WO2005014782A3 (en) Double-stranded ribonucleic acid with increased effectiveness in an organism
ES2171039T3 (en) PRODUCT THAT INCLUDES AT LEAST A double-stranded RNA IN ASSOCIATION WITH AT LEAST ONE INTERFER FOR THE TREATMENT OF VIRAL HEPATITIS.
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
CA2278715A1 (en) Aminooxy-modified oligonucleotides
ATE346918T1 (en) ANTISENSE OLIGONUCLEOTIDES BASED ON BETA-ARABINOSE AND ITS ANALOGUES
WO2006102970A3 (en) Modified short interfering rna
FR2790757B1 (en) OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
CA2070664A1 (en) Antisense oligonucleotide inhibition of papillomavirus
EP1892293A8 (en) Transcription factor decoy
WO2003101394A3 (en) Defensins: use as antiviral agents
WO2003097661A3 (en) Antiviral phosphorothioate oligonucleotides
WO2004037853A3 (en) Quinolones with anti-hiv activity
WO2001066118A8 (en) 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
WO2003031459A3 (en) Modulation of the expression of genes dependent on stat-1
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
WO2002068582A3 (en) Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
IT1320168B1 (en) SYNTHETIC OLIGONUCLEOTIDES THAT CAN INDUCE THE ERYTHROID DIFFERENTIATION.
HUP0400987A2 (en) Anti-virus agent
EP1347061A4 (en) Method of quantifying hiv-1 rna-dna hybrid and diagnosis kit

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP